Dentsply Sirona Reports Third Quarter 2026 Results

News Summary

- **Q3 2026 net sales of $836 million**
- **Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01)**
- **Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29**
- **Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™ portfolio with the launch of the Surity™ Urinary Management System**
- **Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30**

Charlotte, N.C., November 5, 2026 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.

"We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth."

Q3 2026 Summary Results (Reported)

Gross profit and adjusted EBITDA include a $39 million benefit from the refinement of our estimate to eliminate unrealized profit in inventory. The adjustment reduces the reported net loss and increases adjusted net income by approximately $30 million. This amount represents the cumulative impact of the revised estimate and equivalent impacts are not expected in future.

(in millions, except per share amount and percentages)	Q3 26	Q3 25	YoY
Net Sales	$836	$904	*(7.6%)*
Gross Profit	$443	$441	*0.3%*
Gross Margin	52.9%	48.8%	
Net Loss Attributable to Dentsply Sirona	($2)	($427)	*NM*
Diluted Loss Per Share[1]	($0.01)	($2.14)	*NM*

Q3 2026 Summary Results (Non-GAAP)

(in millions, except per share amount and percentages)	Q3 26	Q3 25	YoY
Constant Currency Sales			*(7.0%)*
Adjusted EBITDA	$146	$167	*(13.3%)*
Adjusted EBITDA Margin	*17.3%*	*18.4%*	
Adjusted EPS	$0.29	$0.42	*(29.4%)*

NM - not meaningful
Percentages are based on actual values and may not reconcile due to rounding.
[1] Weighted-average shares outstanding used to calculate diluted loss per share for the third quarter of 2026 excludes potential dilutive common shares.

Q3 2026 Results by Region and Segment (Reported and Non-GAAP)

(in millions, except percentages)

Net Sales by Segment			Percentage Change							
			Three Months Ended September 30, 2026 vs. 2025							
					Americas		EMEA		APAC	
	2026	2025	As Reported[1]	Constant Currency[1]	As Reported	Constant Currency	As Reported	Constant Currency	As Reported	Constant Currency
Connected Technology Solutions	$ 230	$ 259	(11.0)%	(10.1)%	(21.6)%	(21.9)%	(5.5)%	(4.2)%	(4.7)%	(2.5)%
Essential Dental Solutions	343	357	(4.0)%	(3.6)%	(0.6)%	(0.8)%	(7.7)%	(6.5)%	(4.4)%	(4.2)%
Orthodontic and Implant Solutions	171	205	(16.6)%	(16.2)%	(22.9)%	(23.1)%	(13.5)%	(12.3)%	(7.3)%	(7.2)%
Wellspect Healthcare	92	83	10.1%	11.0%	77.3%	78.6%	1.2%	2.0%	(1.0)%	4.1%
Total	$ 836	$ 904	(7.6)%	(7.0)%	(9.4)%	(9.6)%	(6.7)%	(5.6)%	(5.2)%	(4.3)%

(1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.

Cash Flow and Liquidity

Operating cash flow in the third quarter of 2026 was $32 million, compared to $79 million in the third quarter of 2025, primarily driven by unfavorable working capital. Free cash flow, a Non-GAAP measure, in the third quarter of 2026 was $0 million compared to $40 million in the third quarter of 2025. In the third quarter of 2026, the Company repurchased 1.2 million shares of its common stock for a total of approximately $13 million, resulting in a total of $25 million returned to stockholders through share repurchases in the first nine months of 2026. The Company had $195 million of cash and cash equivalents as of September 30, 2026.

2026 Outlook

The Company is updating its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.

Without unreasonable effort, we are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information

Dentsply Sirona's management team will host an investor conference call and live webcast on November 5, 2026 at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at http://register-conf.media-server.com/register/BI087bbe14635a47a484497a4e4376efc9. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona
Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:
Investors:
Suzanne Hatcher
Investor Relations
Investorrelations@dentsplysirona.com

Press:
Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
Publicrelations@dentsplysirona.com

Forward-Looking Statements and Associated Risks

All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any result, expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Net sales	$ 836	$ 904	$ 2,614	$ 2,719
Cost of products sold	393	463	1,251	1,322
Gross profit	443	441	1,363	1,397
Selling, general, and administrative expenses	363	355	1,078	1,055
Research and development expenses	42	37	131	110
Goodwill and intangible asset impairments	3	262	3	497
Restructuring and other (income) expenses	(2)	5	67	18
Operating income (loss)	37	(218)	84	(283)
Other income and expenses:				
Interest expense, net	25	23	71	66
Other income, net	(14)	(11)	(43)	(10)
Income (loss) before income taxes	26	(230)	56	(339)
Provision for income taxes	29	198	33	114
Net (loss) income	(3)	(428)	23	(453)
Less: Net loss attributable to noncontrolling interest	(1)	(1)	(2)	(1)
Net (loss) income attributable to Dentsply Sirona	$ (2)	$ (427)	$ 25	$ (452)
(Loss) earnings per common share attributable to Dentsply Sirona:				
Basic	$ (0.01)	$ (2.14)	$ 0.12	$ (2.27)
Diluted	$ (0.01)	$ (2.14)	$ 0.12	$ (2.27)
Weighted average common shares outstanding:				
Basic	199.2	199.5	199.6	199.3
Diluted	199.2	199.5	200.6	199.3

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share amounts)
(unaudited)

	September 30, 2026	December 31, 2025
Assets		
Current Assets:		
Cash and cash equivalents	$ 195	$ 326
Accounts and notes receivable-trade, net	605	688
Inventories, net	707	642
Prepaid expenses and other current assets	471	367
Total Current Assets	1,978	2,023
Property, plant, and equipment, net	845	861
Operating lease right-of-use assets, net	126	139
Identifiable intangible assets, net	815	974
Goodwill	1,136	1,148
Other noncurrent assets	290	284
Total Assets	$ 5,190	$ 5,429
Liabilities and Equity		
Current Liabilities:		
Accounts payable	$ 238	$ 300
Accrued liabilities	706	700
Income taxes payable	58	30
Notes payable and current portion of long-term debt	215	313
Total Current Liabilities	1,217	1,343
Long-term debt	1,985	2,015
Operating lease liabilities	87	93
Deferred income taxes	74	94
Other noncurrent liabilities	473	544
Total Liabilities	3,836	4,089
Total Equity	1,354	1,340
Total Liabilities and Equity	$ 5,190	$ 5,429

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)

	Nine Months Ended September 30,	
	2026	2025
Cash flows from operating activities:		
Net income (loss)	$ 23	$ (453)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation	110	104
Amortization of intangible assets	136	155
Goodwill asset impairment	—	409
Indefinite-lived intangible asset impairment	3	88
Deferred income taxes	(50)	44
Stock-based compensation expense	25	25
Other non-cash expense	3	13
(Gain) loss on disposal of assets	(7)	—
Changes in operating assets and liabilities:		
Accounts and notes receivable-trade, net	67	(56)
Inventories, net	(78)	(61)
Prepaid expenses and other current assets	(5)	(10)
Other noncurrent assets	(2)	—
Accounts payable	(21)	(9)
Accrued liabilities	(61)	(66)
Income taxes	30	(45)
Other noncurrent liabilities	(2)	(4)
Net cash provided by operating activities	171	134
Cash flows from investing activities:		
Capital expenditures	(128)	(90)
Cash received on derivative contracts	—	10
Cash paid on derivative contracts	—	(9)
Net investment hedge settlements	(17)	—
Proceeds from sale of property, plant, and equipment	4	—
Other investing activities	6	2
Net cash used in investing activities	(135)	(87)
Cash flows from financing activities:		
Cash paid for treasury stock	(25)	—
Proceeds from 364-day bridge loan	—	435
Repayment of 364-day bridge loan	—	(435)
Proceeds (repayments) on short-term borrowings, net	130	(416)
Cash dividends paid	(32)	(96)
Proceeds from long-term borrowings	—	551
Repayments on long-term borrowings	(225)	(3)
Cash paid for deferred financing costs	—	(13)
Other financing activities, net	(6)	(4)
Net cash (used in) provided by financing activities	(158)	19
Effect of exchange rate changes on cash and cash equivalents	(9)	25
Net (decrease) increase in cash and cash equivalents	(131)	91
Cash and cash equivalents at beginning of period	326	272
Cash and cash equivalents at end of period	$ 195	$ 363
Supplemental disclosures of cash flow information:		
Interest paid, net of amounts capitalized	$ 78	$ 65
Non-cash investing activities:		
Property, plant and equipment in accounts payable at end of period	$ 37	$ 25
Exchange of inventory for naming and other rights	$ —	$ 14

Supplemental Information – Reconciliation of GAAP to Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States ("GAAP") with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; adjusted gross profit as a percent of net sales ("Adjusted Gross Margin"); adjusted operating income; adjusted operating income as a percent of net sales ("Adjusted Operating Margin"); adjusted earnings before interest expense, income taxes, depreciation and amortization ("Adjusted EBITDA"); Adjusted EBITDA as a percent of net sales ("Adjusted EBITDA Margin"); adjusted net income (loss); adjusted earnings (loss) per diluted share ("Adjusted EPS"); and Free Cash Flow. These non-GAAP financial measures are used by the Company to measure its performance and management believes these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

The Company has defined the non-GAAP measures used by management as follows:

- ***Constant Currency:*** reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.
- ***Adjusted Operating Income and Margin:*** Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales.
    - Business combination-related costs: costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.
    - Restructuring-related charges and other costs: costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.
    - Goodwill and intangible asset impairments: include charges related to goodwill and intangible asset impairments.
    - Amortization of purchased intangible assets: includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.
    - Fair value and credit risk adjustments: include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments.
- ***Adjusted Gross Profit and Margin:*** gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales. Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.
- ***Adjusted Net Income (Loss):*** net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above and the related income tax impacts of those

items, as well as the tax effects of certain significant and discrete tax adjustments, including benefits and provisions related to changes in realization of deferred tax assets and tax credit carryforwards, as well as other events that affect comparability and are not core to our underlying operational performance.

- ***Adjusted EBITDA and Margin:*** in addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.
- ***Adjusted Earnings (Loss) Per Diluted Share:*** computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.
- ***Free Cash Flow:*** net cash provided by operating activities minus capital expenditures during the same period.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period. The weighted-average diluted shares outstanding used in the calculation of adjusted net loss per diluted share excludes potential dilutive common shares.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)

Beginning in fiscal year 2026, the Company updated its definition of Adjusted Net Income (Loss), a non-GAAP financial measure, to include adjustments for certain significant and discrete tax items, including benefits and provisions related to changes in the realization of deferred tax assets and tax credit carryforwards, as well as other tax-related items that affect comparability and are not considered part of the Company's core operational performance. Prior-period information below has been updated to conform to current period presentation. A reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP financial statements items are as follows:

Three Months Ended September 30, 2026	Gross Profit	Operating Income	Provision for Income Taxes	Net (Loss) Income Attributable to Dentsply Sirona	Diluted (Loss) Earnings per Share
Reported	$ 443	$ 37	$ 29	$ (2)	$ (0.01)
Reported percent net sales	52.9%	4.4%			
Non-GAAP Adjustments:					
Amortization of Purchased Intangible Assets	12	46	11	35	0.17
Restructuring-Related Charges and Other Costs (a)	1	10	2	8	0.04
Goodwill and Intangible Asset Impairments	—	3	1	2	0.01
Business Combination-Related Costs	—	—	—	—	—
Fair Value and Credit Risk Adjustments	—	(1)	—	(1)	—
Income Tax-Related Adjustments (b)	—	—	(17)	17	0.08
Adjusted	$ 456	$ 95	$ 26	$ 59	$ 0.29
Adjusted percent net sales	54.5%	11.5%			
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share					199.2
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share					200.2

(a) Restructuring-Related Charges and Other Costs includes costs from restructuring actions and the new global ERP system, partially offset by a $9 change in estimate for the 2026 restructuring plan. These amounts are on a pre-tax basis.

(b) Income Tax-Related Adjustments includes adjustments for increased valuation allowances for the U.S. of $12, Luxembourg of $3, and Switzerland of $2 and decreased valuation allowances for Germany of $5, along with other various tax adjustments.

Percentages are based on actual values and may not reconcile due to rounding.

Three Months Ended September 30, 2025	Gross Profit	Operating (Loss) Income	Provision for Income Taxes	Net (Loss) Income Attributable to Dentsply Sirona	Diluted (Loss) Earnings per Share
Reported	$ 441	$ (218)	$ 198	$ (427)	$ (2.14)
Reported percent net sales	48.8%	(24.0%)			
Non-GAAP Adjustments:					
Amortization of Purchased Intangible Assets	33	56	15	41	0.21
Restructuring-Related Charges and Other Costs (a)	1	17	(3)	20	0.10
Goodwill and Intangible Asset Impairments	—	262	(1)	263	1.31
Business Combination-Related Costs	—	2	1	1	0.01
Income Tax-Related Adjustments (b)	—	—	(186)	186	0.93
Adjusted	$ 475	$ 119	$ 24	$ 84	$ 0.42
Adjusted percent net sales	52.6%	13.2%			
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share					199.5
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share					200.3

(a) Restructuring-Related Charges and Other Costs includes $5 in costs for the new global ERP system, $4 in costs from various restructuring actions related to employee severance, $4 in executive separation costs, and various other costs. Amounts are on a pre-tax basis.

(b) Income Tax-Related Adjustments includes adjustments for decreased valuation allowances for Luxembourg of $3, along with increased valuation allowances for Germany of $5 and Switzerland of $3, and other various tax adjustments.

Percentages are based on actual values and may not reconcile due to rounding.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)

Reconciliations of reported net loss attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:

	Three Months Ended September 30,	
	2026	2025
Net loss attributable to Dentsply Sirona	$ (2)	$ (427)
Interest expense, net	25	23
Provision for income taxes	29	198
Depreciation[(1)]	36	36
Amortization of intangible assets	46	56
Restructuring-related charges and other costs	10	17
Goodwill and intangible asset impairments	3	262
Business combination-related costs and fair value adjustments	—	2
Fair value and credit risk adjustments	(1)	—
Adjusted EBITDA	$ 146	$ 167
Net sales	$ 836	$ 904
Adjusted EBITDA margin	17.3%	18.4%

(1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.
Percentages are based on actual values and may not reconcile due to rounding.

A reconciliation of free cash flow for the three months ended September 30, 2026 and 2025 is as follows:

	Three Months Ended September 30,	
	2026	2025
Net cash provided by operating activities	$ 32	$ 79
Capital expenditures	(32)	(39)
Free cash flow	$ —	$ 40